CVRx launches landmark BENEFIT-HF trial for cardiac device research

CVRx launches landmark BENEFIT-HF trial for cardiac device research
CVRx starts BENEFIT-HF trial

CVRx has announced the first patient enrollment in the BENEFIT-HF trial at North Central Heart, a division of the Avera Heart Hospital in Sioux Falls, South Dakota.

This groundbreaking trial, led by Dr. Orvar Jonsson, is poised to become one of the largest therapeutic studies for cardiac devices. The BENEFIT-HF trial aims to evaluate innovative approaches in heart failure treatment, reflecting a major research commitment in the field of cardiovascular medicine.

CVRx previously introduced its Barostim device at ISHLT2026, focusing on improved outcomes for heart failure patients beyond standard therapies. The company has also reported that Barostim therapy can boost quality of life in heart failure patients, referencing a case shared by Dr. Savitri Fedson in a recent report. These developments highlight CVRx's ongoing involvement in advancing cardiac device treatments.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.